drugset / Trial / NCT00992732
Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if treatment with HQK-1004 and valganciclovir will result in complete or partial responses in patients with EBV-positive lymphoid malignancies or lymphoproliferative disorders.
Timeline
- Start
- 2010-05
- Primary completion
- 2010-11
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Arginine Butyrate | Small molecule | 1000 mg/kg | Intravenous |
| Subject | Ganciclovir | Small molecule | 5 mg/kg | Intravenous |
| Subject | Valganciclovir | Small molecule | 900 mg | Oral |